Clinical trials: Still Disease
Familial Mediterranean Fever, Still Disease
A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients
This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including…
- Conditions
- Familial Mediterranean Fever, Still Disease, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still Disease
- Trial name
- NCT07517250
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Adult-Onset Still's Disease, AOSD
Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)
The primary objective of the study is to evaluate the efficacy of RPH-104 when administered at a dose of 160 mg on Day 0, Day 7, Day 21 and then once every 2 weeks (Q2W) subcutaneous (SC) in patients with Adult Onset Still's…
- Trial name
- NCT05432960
- Testing
- RPH-104
- Where
- 4 sites in Russia
- Sponsor
- R-Pharm International, LLC
Gastroesophageal Reflux Disease, GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 20 mg to subjects who still had heartburn after receiving rabeprazole 10 mg once daily for at least 4 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Reflux Esophagitis
- Trial name
- NCT01397084
- Testing
- esomeprazole 20 mg
- Volunteers
- 107 people
- Sponsor
- AstraZeneca
Plasma Cell Myeloma
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
This is a multi-center, open-label, Phase 2 treatment extension study in participants with multiple myeloma who are still benefitting from isatuximab based therapy following completion of a Phase 1, 2, or 3 parental study.
- Trial name
- NCT05669989
- Testing
- Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone
- Where
- 37 sites in United States, Australia and 15 more
- Volunteers
- 70 people
- Sponsor
- Sanofi
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this…
- Trial name
- SKYPS (NCT02991469)
- Testing
- Sarilumab SAR153191 (REGN88)
- Where
- 40 sites in Argentina, Canada and 12 more
- Volunteers
- 51 people
- Sponsor
- Sanofi
Adult Onset Still's Disease
A Study to Evaluate Camoteskimab in Participants With Still's Disease
The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease.
- Trial name
- NCT04752371
- Testing
- Camoteskimab (CERC-007, AVTX-007, AEVI-007)
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 5 people
- Sponsor
- Apollo Therapeutics Ltd
Breast Cancer
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without…
- Trial name
- NCT01480674
- Testing
- Trastuzumab
- Where
- 78 sites in France
- Volunteers
- 160 people
- Sponsor
- Hoffmann-La Roche
Juvenile Idiopathic Arthritis
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)
This Phase IV, multicenter, single-arm, open-label study will evaluate the efficacy and safety of tocilizumab in Chinese participants with sJIA with persistent activity and an inadequate response to non-steroidal…
- Trial name
- NCT03301883
- Testing
- Tocilizumab, NSAIDs, CSs
- Where
- 10 sites in China
- Volunteers
- 62 people
- Sponsor
- Hoffmann-La Roche
Active Systemic, Onset Juvenile Idiopathic Arthritis
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
This study has the following objectives: Primary objective: To determine the safety and tolerability of oral ITF2357 in patients with active SOJIA with inadequate response or intolerance to standard therapy with oral steroids and…
- Trial name
- SOJIA (NCT00570661)
- Testing
- ITF2357
- Where
- 5 sites in Romania, Serbia
- Volunteers
- 17 people
- Sponsor
- Italfarmaco
Still's Disease, Including SJIA and AOSD, With MAS or ILD Complications
Managed Access Programs for MAS825, Arumakimig
The purpose of this registration is to list Managed Access Programs (MAPs) related to MAS825, arumakimig
- Trial name
- NCT07889310
- Testing
- Arumakimig
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Cardiac Arrest
Quick ICD Study: Is Extensive Electrophysiological Testing Before, During and After ICD-Implantation Still Necessary ?
The purpose of this study is to evaluate the strategy of implanting an ICD with or without EPS before, during and after ICD-implantation in a randomised controlled trial, using a combined endpoint of major ICD-related adverse…
- Trial name
- Quick ICD (NCT00180362)
- Testing
- procedure
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Juvenile Idiopathic Arthritis
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis
This open-label extension of the JIGSAW studies (WA28117 [NCT01904279] and WA28118 [NCT01904292]) is designed to evaluate the long-term safety and efficacy of subcutaneous (SC) tocilizumab treatment in participants with…
- Trial name
- NCT02165345
- Testing
- Tocilizumab
- Where
- 31 sites in United States, Argentina and 10 more
- Volunteers
- 82 people
- Sponsor
- Hoffmann-La Roche
Systemic Juvenile Idiopathic Arthritis
Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in patients with systemic juvenile idiopathic arthritis (SJIA) having a flare.
- Trial name
- β-SPECIFIC 1 (NCT00886769)
- Testing
- Canakinumab
- Where
- 91 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Assessment of macrophage activation syndrome in Still's disease: retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy
- Conditions
- Macrophage Activation Syndrome (MAS), Still Disease, Juvenile Onset, Still's Disease, Adult-Onset
- Trial name
- AMETISTA (NCT06992505)
- Where
- 2 sites in Italy
- Volunteers
- 32 people
- Sponsor
- Swedish Orphan Biovitrum
Stable Angina
Effectiveness of a Combination of Trimetazidine With One Hemodynamic Agent in Patients Recently Diagnosed With Stable Angina and Still Symptomatic Despite First Line Hemodynamic Therapy
The purpose of this study is to assess in recently diagnosed stable Angina patients symptomatic despite first line hemodynamic therapy, the effect of a combination of this hemodynamic agent with a metabolic one (trimetazidine).
- Trial name
- NCT06298045
- Where
- Romania
- Volunteers
- 600 people
- Sponsor
- Servier Affaires Médicales